Cargando…

Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting

INTRODUCTION: To report 3-year treatment outcomes with intravitreal aflibercept injections for neovascular age-related macular degeneration (nAMD) in routine clinical practice. METHODS: This was a retrospective, single-centre, non-randomized interventional case series analysis. Data from treatment-n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eleftheriadou, Maria, Gemenetzi, Maria, Lukic, Marko, Sivaprasad, Sobha, Hykin, Philip G., Hamilton, Robin D., Rajendram, Ranjan, Tufail, Adnan, Patel, Praveen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258584/ https://www.ncbi.nlm.nih.gov/pubmed/29982914 http://dx.doi.org/10.1007/s40123-018-0139-5

Ejemplares similares

Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sivaprasad, Sobha, et al.
Publicado: (2008)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
por: Gohil, Rishma, et al.
Publicado: (2015)

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial
por: Patel, Praveen J., et al.
Publicado: (2020)

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
por: Gohil, Rishma, et al.
Publicado: (2016)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sivaprasad, Sobha
Publicado: (2008)

A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Gemenetzi, Maria, et al.
Publicado: (2017)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)
por: Sivaprasad, Sobha, et al.
Publicado: (2013)

Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy
por: Keane, Pearse A., et al.
Publicado: (2011)

Correction: Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)
por: Sivaprasad, Sobha, et al.
Publicado: (2013)

Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration
por: Talks, J S, et al.
Publicado: (2017)

Quantitative Autofluorescence in Non-Neovascular Age Related Macular Degeneration
por: Chandra, Shruti, et al.
Publicado: (2023)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Modelling Cost Effectiveness in Neovascular Age-Related Macular Degeneration: The Impact of Using Contrast Sensitivity vs. Visual Acuity
por: Butt, Thomas, et al.
Publicado: (2014)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases
por: Vemala, Roopa, et al.
Publicado: (2010)

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
por: Holz, Frank G, et al.
Publicado: (2016)

Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept
por: Sato, Tomohito, et al.
Publicado: (2021)

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
por: Thomas, Michael, et al.
Publicado: (2013)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review
por: Hanson, Rachel L. W., et al.
Publicado: (2022)

HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: You, Qi Sheng, et al.
Publicado: (2018)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
por: Ross, Adam H., et al.
Publicado: (2020)

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial
por: Mitchell, Paul, et al.
Publicado: (2021)

An exploratory study evaluating the effects of macular carotenoid supplementation in various retinal diseases
por: Crosby-Nwaobi, Roxanne, et al.
Publicado: (2016)

A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1
por: Chorev, Michal, et al.
Publicado: (2023)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel, Praveen J, et al.
Publicado: (2017)

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
por: Nishikawa, Keiichi, et al.
Publicado: (2019)

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
por: Itagaki, Kanako, et al.
Publicado: (2020)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample
por: Hussein, Zaid Rajab, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7sskpn4enl3hs2dnf03ue8keh7